M. Frenk Smrekar, CEO of JAFRAL, Slovenia, will join the 8th World Congress Targeting Therapy in Berlin.
Topic :
Good Manufacturing Practices For Phage Production: Scaling Production. Quality Control And Standardization. Market Access And Commercialization Strategies.
About JAFRAL :
JAFRAL is a world-leading Contract Development and Manufacturing Organization (CDMO) specializing in bacteriophage-based products. With deep expertise in the development and manufacturing of phage therapies, JAFRAL supports a broad spectrum of sectors, including human therapeutics (clinical trial material, magistral products, compassionate use), veterinary medicine, food industry, agriculture and dermatology. JAFRAL’s state-of-the-art manufacturing facilities are equipped to deliver GMP-compliant and non-GMP bacteriophage products with batch capacities of up to 200 liters, fully aligned with FDA, EMA and TGA regulatory standards. The company provides end-to-end services from process and analytical method development to large-scale production tailored to meet the stringent demands of both clinical and commercial use.
The company offers diverse formulation capabilities, including liquid formulations, spray drying, and lyophilization, ensuring flexible and customized solutions for a wide range of therapeutic and industrial applications. JAFRAL has a strong track record in Clinical Trial Material production, having successfully contributed to 12 clinical trials across the United States, Europe and Australia.
Targeting Phage Therapy 2025
June 10-11, 2025 – Berlin, Germany
